Department of Clinical Pharmacy, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266003, China.
Department of Clinical Pharmacy, People's Liberation Army 401 Hospital, Qingdao, China.
Biomed Res Int. 2022 Jul 12;2022:7850658. doi: 10.1155/2022/7850658. eCollection 2022.
Metastasis is the main obstacle for the treatment of gastric cancer (GC), leading to low survival rate and adverse outcomes in CG patients. SLC6A14, a general amino acid transporter, can import all the essential amino acids in a manner dependent on the NaCl-generated osmotic gradients. Herein, we constructed GC cell sublines with high (SGC7901-M and MKN28-M) and low (MKN28-NM and SGC7901-NM) metastatic ability. Putative functional genes advancing GC metastasis were identified using mRNA microarray analysis and High-Content Screening. In particular, most significant change with a dampening trend in the migration potentiality of GC cells emerged after SLC6A14 gene was silenced. SLC6A14 expression was positively correlated with the migrated capability of different GC cell lines, and SLC6A14 was also constitutively expressed in GC patients with venous or lymphatic invasion, lymph node, or distant metastasis and poor prognosis, thus prompting SLC6A14 as a nonnegligible presence in supporting GC migration and invasion. Consistently, SLC6A14 depletion drastically depressed GC metastasis and . Most importantly, pharmacological blockade and gene silence of SLC6A14 both restricted epithelial-mesenchymal transition- (EMT-) driven GC metastasis, in which attenuated activation of the PI3K/AKT/mTORC1 pathway caused by amino acid starvation was involved. In summary, it is conceivable that targeting SLC6A14 has a tremendous promising for the treatment of metastatic GC.
转移是胃癌 (GC) 治疗的主要障碍,导致 CG 患者的生存率低和预后不良。溶质载体家族 6 成员 14(SLC6A14)是一种通用氨基酸转运体,能够以依赖于 NaCl 产生的渗透梯度的方式摄取所有必需氨基酸。在此,我们构建了具有高(SGC7901-M 和 MKN28-M)和低(MKN28-NM 和 SGC7901-NM)转移能力的 GC 细胞亚系。使用 mRNA 微阵列分析和高内涵筛选鉴定了促进 GC 转移的推定功能基因。特别是,在沉默 SLC6A14 基因后,GC 细胞迁移潜力的大部分显著变化呈减弱趋势。SLC6A14 的表达与不同 GC 细胞系的迁移能力呈正相关,并且 SLC6A14 在具有静脉或淋巴侵袭、淋巴结或远处转移和预后不良的 GC 患者中也持续表达,因此促使 SLC6A14 在支持 GC 迁移和侵袭中不容忽视。一致地,SLC6A14 的耗竭极大地抑制了 GC 的转移和侵袭。最重要的是,SLC6A14 的药理学阻断和基因沉默均限制了 EMT 驱动的 GC 转移,其中涉及到由于氨基酸饥饿导致的 PI3K/AKT/mTORC1 通路活性减弱。总之,可以想象,靶向 SLC6A14 具有治疗转移性 GC 的巨大潜力。